#ASCO22: BioNTech says mRNA vaccine safe in 15 of 16 patients with deadly pancreatic cancer

CHICAGO — Pandemic vaccine breakout BioNTech is back with more data on its individualized mRNA cancer jab known as autogene cevumeran in the most common form of pancreatic cancer. While the Genentech-partnered vaccine is in two Phase II trials, BioNTech used this year’s ASCO to present data on a single-site…

...

Click to view original post